Grant: Team Grant: NEURON
Université de Montréal
$100,000.00
A novel paradigm for effective and safer treatment of schizophrenia: biased (ant)agonists with a characterized polypharmacological profile
EF 2018-19
Résumé
Schizophrenia (SZ) is a severe disease affecting 1-2% of the population. Current treatment is associated to side effects such as motor coordination problems, a feeling of the mind slowing down, abnormal electrical activity in the brain, altered heart rhythm, among many others. In addition, a high percentage of patients do not respond (30%) or only partially (additional 30%) to treatment. There is therefore a real need for developing better drugs. The drugs currently used to treat SZ are antipsychotics that act primarily through receptors that belong to a large family of proteins, the G protein-coupled receptors. They are present at the surface of neurons where they recognize and transduce the information of neurotransmitters. One of the main target of antipsychotic drugs is a receptor binding serotonin, a neurotransmitter involved in mood control. However, these drugs are not fully selective and they also act on closely related receptors, the monoamine receptors, resulting in a polypharmacological profile. However, the relative contribution of each receptor to the beneficial and undesired effects is poorly understood. Moreover, each of these receptors control multiple cellular signaling cascades that are differentially regulated by distinct drugs. This phenomenon of 'biased signalling' is an important aspect of drug action. We therefore propose to develop chemical probes with defined biased and polypharmacology profiles to interrogate which signalling activities are responsible for alleviating the different SZ symptoms and which ones underlie the various side effects. For this purpose, we assembled an international team of experts with complementary know-how in computational and medicinal chemistry, molecular pharmacology and cell signalling as well as animal model of SZ. In addition to provide highly original insights into the mode of action of antipsychotics, these studies should open the way to the design of better and safer therapeutics for the treatment of SZ.
Programme
Team Grant: NEURON
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
387321
Name
Bouvier Michel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
German Federal Ministry of Research, Technology and Space (Berlin); Fonds de recherche du Québec - Santé (FRQS); Instituto de Salud Carloss III (Spain)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
A novel paradigm for effective and safer treatment of schizophrenia: biased (ant)agonists with a characterized polypharmacological profile
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Team Grant: NEURON
Keyworddelim
Antipsychotics; Biased Signalling; G Protein-Coupled Receptors; Monoamine Receptors; Resonance Energy Transfer (Bret-Fret); Schizophrenia; Serotonin Receptor; Signalling Pathways
Abstract
Schizophrenia (SZ) is a severe disease affecting 1-2% of the population. Current treatment is associated to side effects such as motor coordination problems, a feeling of the mind slowing down, abnormal electrical activity in the brain, altered heart rhythm, among many others. In addition, a high percentage of patients do not respond (30%) or only partially (additional 30%) to treatment. There is therefore a real need for developing better drugs. The drugs currently used to treat SZ are antipsychotics that act primarily through receptors that belong to a large family of proteins, the G protein-coupled receptors. They are present at the surface of neurons where they recognize and transduce the information of neurotransmitters. One of the main target of antipsychotic drugs is a receptor binding serotonin, a neurotransmitter involved in mood control. However, these drugs are not fully selective and they also act on closely related receptors, the monoamine receptors, resulting in a polypharmacological profile. However, the relative contribution of each receptor to the beneficial and undesired effects is poorly understood. Moreover, each of these receptors control multiple cellular signaling cascades that are differentially regulated by distinct drugs. This phenomenon of 'biased signalling' is an important aspect of drug action. We therefore propose to develop chemical probes with defined biased and polypharmacology profiles to interrogate which signalling activities are responsible for alleviating the different SZ symptoms and which ones underlie the various side effects. For this purpose, we assembled an international team of experts with complementary know-how in computational and medicinal chemistry, molecular pharmacology and cell signalling as well as animal model of SZ. In addition to provide highly original insights into the mode of action of antipsychotics, these studies should open the way to the design of better and safer therapeutics for the treatment of SZ.
Competitiondate
201806
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bouvier, Michel; Kolb, Peter; Selent, Jana
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $100,000~ $0~